SCHEMBL15032053

SCHEMBL15032053

Cc1ccc2c(c1)CN(c1nc(C)nc(C(=O)N3CCC(N4CCO[C@H]5COCC[C@H]54)CC3)c1C)CC2

nearest known ligand 0.44

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CCR2 P41597 2/20 0.44
CCR5 P51681 1/20 0.44
LMNA P02545 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15032046 0.81 CCR2 (0.61) CCR2CCR5LMNA
SCHEMBL15032049 0.81 CCR2 (0.61) CCR2CCR5LMNA
SCHEMBL15033681 0.73 CCR2 (0.52) CCR2CCR5LMNA
SCHEMBL14318466 0.72 AKR1C3 (0.42) CCR2LMNA
SCHEMBL15033679 0.71 CNR2 (0.41) CCR2CCR5LMNA
SCHEMBL14318454 0.70 F2 (0.30)
SCHEMBL15032057 0.70 CCR2 (0.48) CCR2CCR5
SCHEMBL15032044 0.69 CCR2 (0.40) CCR2CCR5
SCHEMBL15032042 0.69 CCR2 (0.40) CCR2CCR5
SCHEMBL14945885 0.69 CCR2 (0.64) CCR2CCR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2721025-B1 NEW SELECTIVE CCR2 ANTAGONISTS BOEHRINGER INGELHEIM INT (DE) 2015-11-25 EP disclosed
US-20130150354-A1 NEW SELECTIVE CCR2 ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-06-13 US disclosed
US-20130150354-A1 NEW SELECTIVE CCR2 ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-06-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130150354-A1 NEW SELECTIVE CCR2 ANTAGONISTS CCR2, CCRL2, CXCR2 CCR2 1/4885CCR5 6/4885LMNA 4785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.